Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New AI Technology Pinpoints Negative Symptoms in Cancer Patients

By HospiMedica International staff writers
Posted on 08 Jan 2019
Researchers from the University of Surrey (England, UK) and the University of California {(UCSF) San Francisco, CA, USA} have developed a new artificial intelligence (AI) tool, which can predict symptoms and their severity throughout the course of a cancer patient's treatment.

In what is believed to be the first study of its kind, the researchers created two machine learning models which are both able to accurately predict the severity of three common symptoms faced by cancer patients - depression, anxiety and sleep disturbance. More...
All these three symptoms are associated with severe reduction in the quality of life of cancer patients.

The researchers analyzed the existing data of the symptoms experienced by cancer patients during the course of their computed tomography X-ray treatment. The team used different time periods during this data to test whether the machine learning algorithms were able to accurately predict when and if the symptoms surfaced. The researchers found that the actual reported symptoms were very close to those predicted by the machine-learning methods.

"These exciting results show that there is an opportunity for machine learning techniques to make a real difference in the lives of people living with cancer. They can help clinicians identify high-risk patients, help and support their symptom experience and preemptively plan a way to manage those symptoms and improve quality of life," said Payam Barnaghi, Professor of Machine Intelligence at the University of Surrey.

"I am very excited to see how machine learning and AI can be used to create solutions that have a positive impact on the quality of life and well-being of patients," said Nikos Papachristou, who worked on designing the machine learning algorithms for the project.

Related Links:
University of Surrey
University of California San Francisco


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.